Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Patients who completed the 12-month core study (NCT00061750)~* Female patients after menarche and who were sexually active, if they used double-barrier contraception, oral contraceptive plus barrier contraceptive, or had undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation~* Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation~Exclusion criteria~* Pregnant or breast feeding patients~* Patients with a history of non-compliance to medical regimens or those considered to be potentially unreliable

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).